Letter to the EditorOsteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis
References (12)
- et al.
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
J Biol Chem
(1998) - et al.
Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease
Atherosclerosis
(2005) - et al.
The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis
J Am Coll Cardiol
(2005) - et al.
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
Genes Dev
(1998) - et al.
The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival
Mol Biol Cell
(2004) - et al.
Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease
Circulation
(2002)
Cited by (63)
Serum OPG/TRAIL ratio predicts the presence of cardiovascular disease in people with type 2 diabetes mellitus
2022, Diabetes Research and Clinical PracticeTRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis
2019, iScienceCitation Excerpt :Much of TRAIL biology has focused on its ability to kill cancer cells. However, low TRAIL concentrations positively associate with CVD in people (Schoppet et al., 2006), suggesting a role that goes beyond that of killing. Indeed, non-apoptotic functions, including stimulation of cell survival, proliferation, and migration, particularly in vascular cells (Azahri et al., 2012; Cartland et al., 2014, 2017; Chan et al., 2010; Di Bartolo et al., 2015; Harith et al., 2015; Kavurma et al., 2008a; Secchiero et al., 2004a, 2004b), and even cancer cells, (Lancaster et al., 2003; Secchiero et al., 2005) have been described.
Therapeutic applications of TRAIL receptor agonists in cancer and beyond
2015, Pharmacology and TherapeuticsLow serum TNF-related apoptosis-inducing ligand (TRAIL) levels areassociated with acute ischemic stroke severity
2015, AtherosclerosisCitation Excerpt :On the other hand, several studies have demonstrated possible anti-inflammatory and anti-atherogenic activity in vitro and in vivo [4,5,20]. The results of previous clinical studies addressing the relationship between low serum TRAIL and cardiovascular diseases can be explained by the anti-inflammatory property of TRAIL [6–10]. Furthermore, our findings of low serum TRAIL level with the increase of acute ischemic stroke severity also could be additional data, which support the anti-inflammatory role of TRAIL.
TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling
2014, AtherosclerosisCitation Excerpt :Furthermore, in vivo studies have found that administration of rTRAIL to diabetic ApoE−/− mice resulted in the stabilization of atherosclerotic plaque by increasing vascular smooth muscle cell (VSMC) content, and reducing overall lesion size [5,6]. Of note, 3 recent in vivo studies have shown that the serum levels of TRAIL are markedly reduced in diabetic patients [7,8] and patients with atherosclerosis [9]. It is also known that diabetes is a risk-factor for cardiovascular disease, and endothelial dysfunction is an early physiological event in cardiovascular disease [10,11].